The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers
- Tomlins, Scott A.
- Rhodes, Daniel R.
- Yu, Jianjun
- Varambally, Sooryanarayana
- Mehra, Rohit
- Perner, Sven
- Demichelis, Francesca
- Helgeson, Beth E.
- Laxman, Bharathi
- Morris, David S.
- Cao, Qi
- Cao, Xuhong
- Andrén, Ove
- Fall, Katja
- Johnson, Laura
- Wei, John T.
- Shah, Rajal B.
- Al-Ahmadie, Hikmat
- Eastham, James A.
- Eggener, Scott E.
- Fine, Samson W.
- Hotakainen, Kristina
- Stenman, Ulf-Håkan
- Tsodikov, Alex
- Gerald, William L.
- Lilja, Hans
- Reuter, Victor E.
- Kantoff, Phillip W.
- Scardino, Peter T.
- Rubin, Mark A.
- Bjartell, Anders S.
- Chinnaiyan, Arul M.
DOIAbstract
SummaryETS gene fusions have been characterized in a majority of prostate cancers; however, the key molecular alterations in ETS-negative cancers are unclear. Here we used an outlier meta-analysis (meta-COPA) to identify SPINK1 outlier expression exclusively in a subset of ETS rearrangement-negative cancers (∼10% of total cases). We validated the mutual exclusivity of SPINK1 expression and ETS fusion status, demonstrated that SPINK1 outlier expression can be detected noninvasively in urine, and observed that SPINK1 outlier expression is an independent predictor of biochemical recurrence after resection. We identified the aggressive 22RV1 cell line as a SPINK1 outlier expression model and demonstrate that SPINK1 knockdown in 22RV1 attenuates...
Add to ORKG